Immunovant, Inc. (IMVT)

Immunovant, Inc. is trading at $43.64, down 0.16% on the session. The 50 day average sits at $37.54 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 63.6, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $38.00 with resistance near $42.92, so that band frames the current range. Average daily movement is roughly $1.55, or about 3.6% of the share price, which is what any stop placement has to allow for. The overall health score of 75 out of 100 combines a trend score of 75, momentum of 82 and a risk score of 65.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.